Convicted triple murderer Erin Patterson has been approved to receive Ozempic inside Victoria’s maximum-security women’s prison, igniting a debate over how far taxpayer-funded healthcare should extend to prisoners serving some of the state’s most serious sentences.

Patterson, 51, is serving life imprisonment at Dame Phyllis Frost Centre after being convicted of murdering Don and Gail Patterson and Heather Wilkinson, and attempting to murder Ian Wilkinson, by deliberately serving a meal containing death cap mushrooms.

She has now been approved for the prescription drug Ozempic following medical assessment inside the prison system.

Reports say the medication was approved amid concerns about her ability to manage her weight and health while living under extremely restrictive conditions that can leave her confined to a small cell for 22 to 23 hours a day.

The decision has prompted criticism from Opposition figures who argue taxpayers should not have to fund expensive weight-management medication for someone convicted of three murders.

Corrections authorities have defended the treatment on a very different principle: prisoners remain patients, and medical decisions are supposed to be made according to clinical need rather than the popularity of the person receiving treatment.

Why Patterson is being prescribed Ozempic

Ozempic contains semaglutide, part of the group of medicines known as GLP-1 receptor agonists.

The drugs have become enormously prominent because they can reduce appetite, slow gastric emptying and assist with blood-glucose control.

In Australia, however, there is an important regulatory distinction.

Ozempic itself is registered by the Therapeutic Goods Administration for adults with insufficiently controlled type 2 diabetes.

Wegovy, which also contains semaglutide, is the version specifically registered for chronic weight management in people meeting relevant obesity or overweight criteria.

Doctors can prescribe medicines outside their registered indication when they consider that medically appropriate, but that makes it inaccurate to describe Ozempic simply as an Australian-approved weight-loss drug without qualification.

Public reporting about Patterson’s prescription has focused on weight management and the limited opportunities for exercise created by her prison regime.

Authorities have not publicly released her complete medical records, nor should they be expected to.

The relevant public fact is that clinicians have approved the medication on medical grounds.

Prison conditions have already become a major legal issue

Patterson’s physical environment inside Dame Phyllis Frost Centre is central to the controversy because it has already played an unusually significant role in her sentence.

Her lawyers have told courts she spends approximately 22 to 23 hours each day inside a cell measuring about four metres by two metres.

They argue those conditions amount to solitary confinement under international standards that define solitary confinement by lengthy daily isolation without meaningful human contact.

Victorian prosecutors dispute that description.

During Patterson’s August appeal hearing, Director of Public Prosecutions counsel accepted that her environment was restrictive but argued it should not necessarily be categorised as solitary confinement in the legal sense advanced by the defence.

The distinction is more than semantic.

When Justice Christopher Beale sentenced Patterson in September 2025, he specifically considered the harsh conditions she had experienced and the likelihood of continued isolation.

He concluded those circumstances should have some practical effect on sentence and ultimately imposed life imprisonment with a 33-year non-parole period.

Without a non-parole period, Patterson would have had no possibility of release.

Prosecutors are now appealing that decision, arguing the seriousness of three murders and one attempted murder warranted either life without parole or a considerably harsher minimum term.

Her conviction is also under appeal

Patterson has not accepted the jury’s verdicts.

Her lawyers appeared before the Victorian Court of Appeal in August seeking to overturn her convictions and secure a retrial.

They relied on seven grounds, including arguments concerning aspects of the jury process, evidentiary decisions and the way the prosecution conducted parts of the trial.

The Crown opposed every ground and argued the evidence against Patterson was overwhelming.

At the same time, the DPP pursued its separate appeal against the sentence.

The Court of Appeal reserved its judgment after hearing both matters.

As of September 10, no final appellate ruling has been announced, meaning Patterson remains convicted and continues serving the existing life sentence with the 33-year non-parole period.

Why taxpayers pay for prisoners’ healthcare

The political controversy surrounding Ozempic raises a broader question that extends well beyond Erin Patterson.

People sent to prison lose their liberty.

They do not lose all access to medical treatment.

Victoria’s prison health framework is administered through Justice Health and contracted health providers, with health centres operating inside prisons to provide general practitioners, nurses and other services.

The stated aim of the Victorian system is to deliver healthcare of a quality and standard broadly equivalent to that available through the public health system outside prison, while recognising that the correctional environment creates practical limitations.

That principle means a doctor’s decision is not ordinarily supposed to depend on whether a prisoner is sympathetic, notorious or convicted of an offence that has generated public outrage.

Prisons are responsible for the people they detain.

Because prisoners cannot freely choose their own doctor, visit a pharmacy or leave custody to obtain ordinary healthcare, the state assumes responsibility for providing necessary treatment.

That is why the cost ultimately falls to taxpayers.

The same principle covers treatment for diabetes, heart disease, cancer, mental illness, infections and other health conditions.

The difficult question in Patterson’s case is not whether prisoners deserve any healthcare.

It is whether a medication popularly associated with weight loss meets a sufficiently strong medical need to justify public funding in her circumstances.

Corrections authorities say that is a clinical question.

Critics want it treated as a question of public expenditure and fairness.

Opposition attacks the decision

Victorian Opposition figures have seized on the approval as evidence that the prison system’s priorities are wrong.

The criticism is politically potent because Ozempic and related GLP-1 medicines can be expensive, while Australians outside prison may face significant out-of-pocket costs or difficulty obtaining particular treatments.

For someone paying privately for weight-management medication, the idea that a convicted triple murderer can receive treatment through a taxpayer-funded prison system is inevitably confronting.

But that comparison can also oversimplify how custodial healthcare works.

The prison system is not providing Patterson with a reward for good behaviour or a luxury benefit attached to her sentence.

The stated basis is medical assessment.

If clinicians determine that untreated obesity, diabetes or another metabolic condition poses a health risk, Corrections is responsible for managing that risk just as it is required to manage other illnesses.

The state also has a practical interest in preventing serious disease.

Emergency treatment, hospitalisation and complications arising from uncontrolled chronic illness can ultimately cost substantially more than earlier medical intervention.

Victoria’s prison healthcare has faced intense scrutiny

Decisions about prisoners’ medical treatment are being made against a history of serious criticism of custodial healthcare in Victoria.

The death of Veronica Nelson at Dame Phyllis Frost Centre in January 2020 became one of the most significant examples.

A coronial inquest later found her death was preventable and identified serious failures in the medical care she received while in custody.

The coroner made 39 recommendations, many involving improvements to healthcare, oversight and the treatment of people entering prison with complex health needs.

Victoria’s Equal Opportunity and Human Rights Commission has subsequently reviewed how Corrections Victoria and Justice Health implemented recommendations arising from that case.

The lesson for authorities is uncomfortable but clear: withholding, delaying or inadequately managing healthcare in prison can itself lead to catastrophic consequences.

That history helps explain why Corrections officials emphasise clinical decision-making when controversial prisoners receive treatment.

A prisoner’s crime does not make preventable medical deterioration acceptable.

Ozempic is not a risk-free cosmetic treatment

The public discussion can also give the impression that GLP-1 drugs are simple cosmetic injections.

They are prescription medicines requiring medical supervision.

The TGA has warned that drugs in this class can cause important adverse effects and recently strengthened product warnings around a rare but potentially severe eye disorder.

GLP-1 medicines can also delay gastric emptying, an effect relevant to surgery and deep sedation because it can increase the risk of stomach contents being inhaled into the lungs.

Prescribing therefore involves balancing possible benefits with medical risks.

That is another reason Patterson’s treatment should not be presented merely as Corrections handing out a popular slimming product.

The decision places responsibility on medical practitioners to determine whether semaglutide is appropriate for her individual circumstances and to monitor treatment accordingly.

The controversy also exposes the cost of isolation

The debate over Ozempic cannot be completely separated from the conditions in which Patterson is being held.

Her isolation has largely been justified by safety and security concerns arising from the extraordinary notoriety of the case.

But keeping somebody locked in a small cell for most of the day inevitably affects opportunities for movement, social interaction and ordinary prison activities.

That can create physical and psychological health consequences that Corrections must then manage.

In other words, the state may simultaneously be imposing restrictive conditions for safety reasons and paying for healthcare needed partly because those same conditions make normal health management more difficult.

That tension was already recognised by the sentencing judge and has now returned in a very different form through the Ozempic debate.

A punishment debate disguised as a healthcare debate

Much of the public anger ultimately comes down to what imprisonment is supposed to mean.

For some Australians, a life sentence for crimes as serious as Patterson’s should involve deprivation extending well beyond the loss of freedom.

From that perspective, taxpayers paying for a costly medication associated with weight reduction feels inconsistent with punishment.

The correctional healthcare model operates on another principle.

The punishment imposed by the court is imprisonment.

It is not untreated disease.

That does not mean every treatment requested by a prisoner must be supplied. Medical necessity, clinical evidence, safety and available resources all remain relevant.

But it does mean the moral gravity of a conviction is not supposed to replace a medical assessment.

That principle becomes most difficult to defend publicly when the patient is one of Australia’s most notorious prisoners.

The final word may still belong to the courts

Patterson’s legal situation remains unsettled.

She is currently a convicted triple murderer serving life with a 33-year non-parole period.

Her appeal against conviction has been heard but not decided.

The prosecution’s attempt to remove or extend her chance of parole is also awaiting judgment.

Her prison conditions continue to be reviewed and could change over time.

So too could her treatment plan.

For now, however, the Ozempic approval stands as another unusual consequence of an extraordinary case.

It has created an easy political headline about taxpayers financing a weight-loss injection for a murderer.

The underlying issue is more difficult.

Victoria has a legal and ethical responsibility to provide healthcare to people it imprisons, including people whose crimes have horrified the community.

The legitimate debate is therefore not whether Erin Patterson has forfeited the right to healthcare.

It is whether this particular treatment is clinically justified, appropriately supervised and consistent with the standards applied to other prisoners with comparable medical needs.

That is a question for which public scrutiny is entirely appropriate.

But the answer ultimately has to come from medicine rather than anger at the prisoner receiving it.